Deloitte September 3, 2024

What’s on the horizon for the advanced therapy (AT) market? Our survey of advanced therapy developers (ATDs), advanced therapy manufacturing organizations (ATMOs), and health care providers (HCPs) and payers reveals a shared optimism and pinpoints key areas to watch. Explore cell and gene therapy insights that can help steer decision-making in the future of personalized medicine.

Insights from the frontlines of advanced therapy

Dive into the findings from our 2024 state of the advanced therapy industry report, highlighting important trends and insights from 376 industry stakeholders across the cell and gene therapy market. Our survey, expanded this year to capture diverse viewpoints, sheds light on optimism in the industry, growth strategies, and pressing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech, Precision Medicine
Related Articles:
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Oncologist talks personalized medicine for pancreatic cancer
AI offers a step above genomic solutions
How Mayo Clinic is using real-world data to advance precision medicine
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Share This Article